Sabby Management’s Grace Therapeutics GRCE Stock Holding History

Sabby Management’s Portfolio GRCE Stock Details GRCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-5,729	Closed	-$229K	–	131
2018 Q4	$229K	Buy	+5,729	New	+$250K	0.05%	68

Other funds holding GRCE

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Sabby Management's GRCE Position: Q1 2019 in Review

Sabby Management sold out of Grace Therapeutics (GRCE) in Q1 2019, closing a stake of 5,729 shares — an estimated $229K sold.

Sabby Management first reported a position in GRCE in Q4 2018 and held it in 1 quarter. The position peaked at $229K in Q4 2018. 14 funds tracked by Wall St. Rank hold GRCE as of Q1 2019.

Sabby Management reported no remaining Grace Therapeutics position as of Q1 2019 after selling out during the quarter.
Sabby Management sold 5,729 Grace Therapeutics shares in Q1 2019, an estimated $229K.
Sabby Management first reported a position in Grace Therapeutics in Q4 2018 and held it in 1 quarter.
Sabby Management's Grace Therapeutics position peaked at $229K in Q4 2018.
14 funds tracked by Wall St. Rank held Grace Therapeutics as of Q1 2019.

Based on Sabby Management's 13F filing for Q1 2019, filed 15 May 2019.